Nucl Med Mol Imaging.
2017 Sep;51(3):212-216. 10.1007/s13139-016-0416-y.
What Do We Measure in Oncology PET?
- Affiliations
-
- 1Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea. growthkim@hanmail.net, ilikechopin@me.com
- 2Department of Nuclear Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan National University, Yangsan, Korea.
- KMID: 2396578
- DOI: http://doi.org/10.1007/s13139-016-0416-y
Abstract
- Positron emission tomography (PET) has come to the practice of oncology. It is known that 18F-fluorodeoxyglucose (FDG) PET is more sensitive for the assessment of treatment response than conventional imaging. In addition, PET has an advantage in the use of quantitative analysis of the study. Nowadays, various PET parameters are adopted in clinical settings. In addition, a wide range of factors has been known to be associated with FDG uptake. Therefore, there has been a need for standardization and harmonization of protocols and PET parameters. We will introduce PET parameters and discuss major issues in this review.
